Abstract
Investments to reduce the spread of antimicrobial resistance (AMR) in the European Union have been made, including efforts to strengthen prudent antimicrobial use. Using segmented regression, we report decreasing and stabilising trends in data reported to the European Surveillance of Antimicrobial Consumption Network and stabilising trends in data reported to the European Antimicrobial Resistance Surveillance Network. Our results could be an early indication of the effect of prioritising AMR on the public health agenda.
Keywords:
Antimicrobial consumption; Escherichia coli; Klebsiella pneumoniae; antimicrobial resistance; bacterial infections; carbapenem; defined daily dose; fluoroquinolone; third-generation cephalosporin.
MeSH terms
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Antimicrobial Stewardship / trends*
-
Cephalosporins / administration & dosage
-
Cephalosporins / pharmacology
-
Cephalosporins / therapeutic use
-
Drug Resistance, Multiple, Bacterial / drug effects
-
Drug Utilization / trends*
-
Escherichia coli / drug effects*
-
Escherichia coli / isolation & purification
-
Escherichia coli Infections / drug therapy*
-
Escherichia coli Infections / microbiology
-
European Union
-
Fluoroquinolones / administration & dosage
-
Fluoroquinolones / pharmacology
-
Fluoroquinolones / therapeutic use
-
Humans
-
Klebsiella Infections / drug therapy*
-
Klebsiella Infections / microbiology
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / isolation & purification
-
Microbial Sensitivity Tests
-
Population Surveillance
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
Fluoroquinolones